ARS Pharmaceuticals (SPRY) News Today $15.39 +0.99 (+6.88%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$15.45 +0.06 (+0.38%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”June 15 at 6:55 AM | msn.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.9% - Here's WhyJune 13 at 2:47 PM | marketbeat.comCantor Fitzgerald Predicts SPRY FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates SPRY FY2026 EarningsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for ARS Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per shJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Two Sigma Investments LP lowered its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 54.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 98,078 shares of the company's stocJune 6, 2025 | marketbeat.comBank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Bank of America Corp DE lowered its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 160,958 shares of the company's stock after selling 18,906 shares dJune 5, 2025 | marketbeat.comAmeriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Ameriprise Financial Inc. increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 113.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,376 shares of the company's stock after purchasing an additiJune 3, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's WhyARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.3% - Here's WhyMay 31, 2025 | marketbeat.comARS Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comMillennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Millennium Management LLC raised its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 93.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 939,278 shares of the company's stockMay 26, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to SellWall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday.May 24, 2025 | marketbeat.comWoodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Woodline Partners LP grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 13.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,119,283 shares of the company's stock after buying an additional 133,276 sharMay 24, 2025 | marketbeat.comNorthern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Northern Trust Corp boosted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 478,153 shares of the company's stock after purchasing an aMay 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy reMay 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 SharesMay 23, 2025 | insidertrades.comRafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Rafferty Asset Management LLC lifted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 72.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,372 shares of the compaMay 23, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LPWexford Capital LP lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 48.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 369,497 shares of the company's stock after acquiring an additional 121,150May 21, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company cut its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 58.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,526 shares of the company's stock after selling 27,328 shares during the period. ThMay 21, 2025 | marketbeat.comFY2025 EPS Estimates for SPRY Cut by Cantor FitzgeraldARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now expects that the compaMay 20, 2025 | marketbeat.comLeerink Partnrs Has Bearish Outlook for SPRY Q2 EarningsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the coMay 20, 2025 | marketbeat.comWilliam Blair Brokers Lower Earnings Estimates for SPRYARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a report issued on Wednesday, May 14th. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($0.44)May 20, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. reduced its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 101,397 shares of the company'sMay 19, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Price T Rowe Associates Inc. MD trimmed its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 95.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,918 shares of the company's stock after sellingMay 19, 2025 | marketbeat.comEarnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecastMay 16, 2025 | uk.investing.comPanoramic Capital LLC Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Panoramic Capital LLC bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 45,806 shares of the company's stock, valued at approximately $483,000. SeveralMay 16, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stake Lowered by Nextech Invest Ltd.Nextech Invest Ltd. decreased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 936,729 shares of the company's stock afterMay 16, 2025 | marketbeat.comNicholas Investment Partners LP Sells 29,753 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Nicholas Investment Partners LP decreased its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 14.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,018 shares of the company's stock after sellingMay 16, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comWhat You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade TodayMay 15, 2025 | finance.yahoo.comMiura Global Management LLC Has $1.79 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Miura Global Management LLC cut its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 37.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,000 shares of the comMay 15, 2025 | marketbeat.comARS Pharmaceuticals Falls After Wider-Than-Expected 1Q LossMay 14, 2025 | marketwatch.comARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)May 14, 2025 | globenewswire.comBalyasny Asset Management L.P. Purchases 322,423 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Balyasny Asset Management L.P. grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 1,431.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 344,941 shares of the company's stock after acquiring an additional 322,423 shares during theMay 14, 2025 | marketbeat.comARS Pharmaceuticals's Earnings: A PreviewMay 14, 2025 | benzinga.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Voya Investment Management LLCVoya Investment Management LLC lifted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 67,277 shares of the company's stock after purchasing an additional 19,May 11, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by DAFNA Capital Management LLCDAFNA Capital Management LLC lowered its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,790 shares of the company's sMay 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Deerfield Management Company L.P. Series CDeerfield Management Company L.P. Series C lessened its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,514,657 shares of the coMay 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Ancora Advisors LLCAncora Advisors LLC lowered its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 82.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,000 shares of the company's stock after selling 29,000 sharesMay 10, 2025 | marketbeat.comARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 KilogramsMay 7, 2025 | globenewswire.comAlyeska Investment Group L.P. Acquires 1,128,724 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Alyeska Investment Group L.P. boosted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 903.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,253,724 shares of the company's stock after purchMay 7, 2025 | marketbeat.comInvesco Ltd. Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Invesco Ltd. reduced its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,988 shares of the company's stock after selling 105,623 shares duringMay 6, 2025 | marketbeat.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Marshall Wace LLPMarshall Wace LLP cut its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 32.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,906 shares of the company's stock after selling 24,973 sharesMay 5, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Holdings Lifted by Barclays PLCBarclays PLC increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 41.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,180 shares of the company's stock after acquiMay 5, 2025 | marketbeat.comARS Pharmaceuticals Partners with ALK for Neffy PromotionMay 3, 2025 | investing.comARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on ThursdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-ars-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffyMay 3, 2025 | msn.comARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. PediatriciansMay 2, 2025 | globenewswire.comTower Research Capital LLC TRC Has $481,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Tower Research Capital LLC TRC lifted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 958.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,576 shares of the company's sMay 2, 2025 | marketbeat.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.980.89▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼85▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVL News Today AXSM News Today ADMA News Today PCVX News Today AKRO News Today RYTM News Today ZLAB News Today PTCT News Today CYTK News Today RNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRY Stock Free SPRY Stock Alerts